BHC · Bausch Health Companies Inc.
Market Cap
$2.17B
Shares
373.99M
Volume · Oct 2
3.28M
Avg daily vol (3M)
3.23M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.80
Open$5.73
Day$5.61–5.87
52W close$4.43–7.90
Avg vol 30d2.4M
Short int8.6M · 2.3% float · 3.1d
Short vol63%
Last earningsJul 29, 2026
DataJan 2020–Oct 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 28, 2026
Est · unconfirmed
· in 3 wks
filed Jul 30, 2026
call held Jul 29, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$10.85B
Trailing 12 months
Net income (TTM)
−$1.10B
Trailing 12 months
Revenue growth YoY
+12.7%
Year over year
Operating margin
8.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
66.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$18.92B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.3%
Year over year · more shares
Price change (1Y)
-11.5%
Trailing year
Short interest
2.3%
Latest settlement · 3.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+0%
above
Price vs 50-day avg
−5%
below
RSI (14)
46
neutral
MACD trend
Positive
52-week position
39%
mid-range
Momentum
relative strength
1-month return
−14%
trailing
6-month return
+1%
trailing
YTD return
−17%
this year
Relative strength
−11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
2 of 224 funds reported for Sep 30 · net +4.6K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.31% of float · ▲ +5.0% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
224 holders — near 3-yr low, contrarian setup
Squeeze score
49
elevated · 0–100
Fundamentals
Revenue growth
−10%
Y/Y
EPS growth
+423%
Y/Y
Free cash flow
$1.0B
Balance sheet
$19.5B
net debt
Quant / Vol
risk profile
Volatility
56%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 29, 2026
Revenue growth vs. Prior Year
· full year 2026 (BHC excl. B+L)
Initiated
4% – 6%
Adj. EBITDA1 growth vs. Prior Year
· full year 2026 (BHC excl. B+L)
Non-GAAP
Initiated
8% – 11%
Guided vs delivered
· last 3 settled
Full year revenue
Full year 2023
guided $8.35B – $8.55B
$8.76B
Beat +3.6%
Revenue
2021
guided $8.6B – $8.8B
$8.43B
Miss −3.1%
Revenue
full-year 2020
guided $7.8B – $8B
$8.03B
Beat +1.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+0%
Bullish
Price vs 50-day avg
−5%
Neutral
RSI (14)
46
Neutral
MACD trend
Positive
Bullish
52-week position
39%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $6 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
2 of 224 funds reported for Sep 30 · net +4.6K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.31% of float · ▲ +5.0% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
224 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $4
Now $6 · 39%
Range high $8
vs 200-day avg +0%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BHC
this stock
Bausch Health Companies Inc.
|
$2.17B | -16.5% | -9.8% | — | 2.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BHC | +1.9% | -14.2% | +1.4% | -0.5% | -16.6% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +2.2% | -13.7% | -10.8% | -1.4% | -29.4% |